|
Postoperative chemotherapy
|
Total (n = 131)
|
UFS (n = 64)
|
NAC (n = 67)
|
NAC (GS) (n = 62)
|
P value* (UFS v.s. NAC)
|
P value* (UFS v.s. NAC (GS))
|
|---|
|
Gemcitabine (monotherapy or combination therapy)
|
80
|
39
|
41
|
36
|
0.855
|
1.000
|
|
S-1 (monotherapy or combination therapy)
|
93
|
45
|
48
|
45
|
0.692
|
0.681
|
|
CDDP plus gemcitabine or S-1
|
6
|
6
|
0
|
0
|
0.013
|
0.028
|
|
Erlotinib plus gemcitabine
|
2
|
2
|
0
|
0
|
0.244
|
0.496
|
|
Paclitaxel (monotherapy)
|
1
|
1
|
0
|
0
|
1.000
|
0.496
|
|
GS
|
7
|
4
|
3
|
3
|
0.718
|
1.000
|
|
GnP
|
40
|
14
|
26
|
23
|
0.035
|
0.051
|
|
FOLFIRINOX
|
12
|
2
|
10
|
10
|
0.030
|
0.014
|
- UFS upfront surgery, NAC neoadjuvant chemotherapy, S-1 tegafur/gimeracil/oteracil, GS gemcitabine plus S-1, CDDP cisplatin, GnP gemcitabine plus nab-paclitaxel, FOLFIRINOX 5-fluorouracil, leucovorin, irinotecan, oxaliplatin
- *Cases without information are excluded from calculation of P values
